Letters Dabigatran v warfarin

Authors’ reply to Zermansky and Khatib

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d7718 (Published 13 December 2011) Cite this as: BMJ 2011;343:d7718
  1. Dyfrig A Hughes, professor of pharmacoeconomics1,
  2. Joshua Pink, PhD student1,
  3. Steven Lane, lecturer in medical statistics2,
  4. Munir Pirmohamed, professor of clinical pharmacology3
  1. 1Centre for Health Economics and Medicines Evaluation, Institute of Medical and Social Care Research, Bangor University, Bangor, Gwynedd LL57 1UT, UK
  2. 2Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool, UK
  3. 3Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool. UK
  1. d.a.hughes{at}bangor.ac.uk

Zermansky and Khatib raise several points regarding our economic evaluation of dabigatran.1 In line with accepted health economic methods,2 we used the current list price of dabigatran. Although the availability of generics affects future pricing, new entrants have little effect on the price of the first to market drug.3

We assumed that dabigatran would have no effect on anticoagulation clinics. …

View Full Text

Log in

Log in through your institution


* For online subscription